# VERU earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VERU) · [Earnings tab](https://www.lopjlb.com/stock/VERU?tab=earnings) Updated: 2026-08-10T02:47:01 Quarters analyzed: 8 ## Cross-quarter narrative Across the eight earnings CallCards, Veru’s story shifts from an early focus on commercial demand and cost compression toward an increasingly clinical‑development‑centric narrative. In 2024 Q2 the company highlighted growing public‑sector demand for its FC2 condom, a disrupted US prescription channel, and a compressed gross margin driven by product‑mix changes and an inventory reserve. A $35.2 M equity raise funded enobosarm Phase IIb work while oncology and ARDS programs were paused. The subsequent quarters (2024 Q3, 2025 Q2‑Q4, 2026 Q1‑Q2) contain few updates, underscoring limited operational activity. A turning point arrives in 2025 Q1 when Veru announced positive Phase IIb results for enobosarm, sold the FC2 business, and disclosed a cash runway of roughly 15 months, flagging the need for additional financing. Safety‑related GI dropouts, regulatory hurdles for sabizabulin, and market differentiation concerns were also raised. Later calls (2025 Q3, 2026 Q1‑Q2) emphasize successive Phase IIb combination studies (enobosarm + semaglutide), FDA engagement on trial design, and incremental capital raises that extend cash through 2027. Throughout, management tone fluctuates, but the overarching trend is a pivot from near‑term commercial execution to advancing a pipeline of obesity‑focused therapeutics while managing a constrained financial position. ## Latest CallCard · Q2 Veru reports positive Phase IIb quality data for enobosarm+sema in sarcopenic obesity; Phase IIb plateau study enrolling with 36-week interim expected Q1 2027; cash $27.6M funds ops beyond interim. No formal guidance. Net loss $3.1M continuing ops. R&D/SG&A down QoQ. Public offering raised $23.4M Oc **Guidance:** vague — No formal financial guidance provided; management states cash expected to fund operations beyond Phase IIb plateau interim analysis. **Tone:** mgmt 0.7 · Q&A pressure 0.5 · divergence 0.2 Prepared remarks highlight positive Phase IIb quality results, large market opportunity, on-track enrollment for plateau study interim analysis, and cash runway beyond interim. ### Demand visibility Large addressable market cited but no near-term demand visibility as enobosarm is in clinical development. Management cites >1B global obesity, ~30M US sarcopenic obesity, ~20M US Medicare Part D enrollees ≥65 with obesity; however, enobosarm remains in Phase II with no commercial product yet. ### Margins / costs No product revenue; R&D and SG&A decreasing as Phase IIb quality study winds down. R&D fell to $3.1M from $3.9M QoQ due to Phase IIb quality study completion; SG&A fell to $4.1M from $5.2M on lower share-based comp; net loss $3.1M continuing ops. ### Capital allocation Capital allocated to Phase IIb plateau study; $23.4M raised in Oct 2025 offering extends cash runway beyond interim analysis. Public offering of common stock and warrants yielded $23.4M net proceeds; cash $27.6M as of Mar 31, 2026; operating cash burn $15.1M over 6 months; investing inflows from Onconetix equity sales ($3.2M) and FC2 settlement ($0.3M). ### Milestones - **Phase IIb quality study (enobosarm + semaglutide)** [delivered]: Positive results showing preservation of lean mass, physical function, greater fat loss in older patients with sarcopenic obesity. - **Phase IIb plateau study (enobosarm + semaglutide)** [on_track]: Enrolling ~ ## Quarter one-liners - **2026 Q2:** Veru reports positive Phase IIb quality data for enobosarm+sema in sarcopenic obesity; Phase IIb plateau study enrolling with 36-week interim expected Q1 2027; cash $27.6M funds ops beyond interim. No formal guidance. Net loss $3.1M continuing ops. R&D/SG&A down QoQ. Public offering raised $23.4M Oc - **2026 Q1:** Veru Q1 FY26: Novosarm Phase 2b PLATO study initiating this quarter, FDA confirmed two regulatory pathways for combo with GLP-1, cash $33M funds ops through 2027 interim analysis.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlighted positive Phase 2b quality results, FDA regulatory clari - **2025 Q4:** — - **2025 Q3:** Veru reports positive Phase 2b data for Inovasaram + semaglutide showing 100% lean mass preservation, 42% greater fat loss, and reduced weight regain; FDA end-of-Phase 2 meeting expected this quarter to define Phase 3 design and capital needs.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management hig - **2025 Q2:** — - **2025 Q1:** Veru reported positive Phase 2b results for enobosarm, expects Q2 2025 readout of the extension, sold its FC2 condom business and has cash to year‑end but needs more capital for future trials. - **2024 Q3:** — - **2024 Q2:** — ## Theme arcs - **Clinical development progress** (improving): Multiple Phase IIb studies initiated or delivered, including enobosarm extensions, combination trials, and regulatory pathway clarification. - **Financial runway** (deteriorating): Cash sufficient only to year‑end in 2025 Q1, prompting equity raises in 2025 and 2026 to fund operations. - **Market demand visibility** (stable): Early public‑sector demand for FC2 noted, but later quarters lack demand updates as focus shifts to trials. - **Management tone** (new): Management confidence rises in 2025 Q1 and 2026 Q1 after positive data, but overall guidance remains vague. ## Fear persistence - **Safety (GI side effects)** [new]: ~13% dropout in Phase IIb enobosarm study noted in 2025 Q1. - **Regulatory (Sabizabulin IND)** [new]: Requirement for chronic toxicology and IND submission by H1 2026 mentioned in 2025 Q1. - **Financial (cash runway)** [new]: Cash sufficient only to year‑end, runway ~15 months disclosed in 2025 Q1. - **Clinical (enobosarm extension uncertainty)** [new]: Uncertainty whether enobosarm will prevent fat regain noted in 2025 Q1. - **Market (GLP‑1 differentiation)** [new]: Need to differentiate from GLP‑1 therapies highlighted in 2025 Q1. ## Guidance path 2024 Q2:vague → 2024 Q3:vague → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/VERU`